Cargando…
Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura
Survivors of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) are exposed to clinical relapses when a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13 (ADAMTS13) activity decreases during follow‐up. Although preemptive rituximab usually improves ADAMTS13 acti...
Autores principales: | Comparon, Celine, Galicier, Lionel, Rebibou, Jean Michel, Coppo, Paul, Benhamou, Ygal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098822/ https://www.ncbi.nlm.nih.gov/pubmed/36271897 http://dx.doi.org/10.1111/ejh.13886 |
Ejemplares similares
-
More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022) -
Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination
por: Picod, Adrien, et al.
Publicado: (2022) -
Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura
por: Pereira, Leydi C. Velasquez, et al.
Publicado: (2020) -
Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura
por: Stubbs, Matthew J., et al.
Publicado: (2021) -
Predictive Scores for Early Identification of Immune-Mediated Thrombotic Thrombocytopenic Purpura: Room for Improvement?
por: Joseph, Adrien, et al.
Publicado: (2022)